{"id":"NCT00175877","sponsor":"UCB Pharma","briefTitle":"A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2005-09-15","resultsPosted":"2013-03-08","lastUpdate":"2020-03-26"},"enrollment":857,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"An open ended study in which patients who completed the double-blind study CDP870-027 \\[NCT00152386\\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 Years","timeFrame":"From first dose of CZP to the end of the open-label study (approximately 7 years)","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":94.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":121,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","Chile","Croatia","Czechia","Estonia","Finland","France","Hungary","Israel","Latvia","Lithuania","Mexico","New Zealand","Russia","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["32100960","22596211","22589265","21484766","29246162","19015207"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":352,"n":846},"commonTop":["Hypertension","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Rheumatoid arthritis"]}}